Anticancer treatment has been impacted significantly by genomics in the last decade. In fact, the therapeutic effect and/or adverse events of a given drug is highly influenced by the genotype of the patient. Pharmacogenomics / Pharmacogenetics, which studies the interaction of genome-drug response, can evaluate the associations between drug efficacy/toxicity and variation in drug pharmacokinetics and pharmacodynamics characteristics. These characteristics include biotransformation, interactions with the receptor and other drug targets, and drug transport. All these mechanisms, controlled often by pharmacogenes, could lead to the resistance of cancer cells by exposing it to a lower therapeutic dose of the active molecule. By understanding the relationship between genome variation and drug response, we can optimize and improve anticancer treatment of the patient, called personalized or precise medicine.
Recently, new genetic variants related to anticancer therapy and cancer resistance, a major obstacle for successful anticancer treatment, have been found due to the technology of next generation sequencing. Furthermore, scientists estimate that the number of variants in pharmacogenes, for example cytochrome P450 genes, ATP-binding cassette (ABC) transporters, and others, are much greater than predicted. Also, most variant alleles in pharmacogenes are rare variants (minor allele frequency (MAF) < 1%) and it has been reported that these alleles play an important role in the pharmacogenomic / pharmacogenetics prediction of drug response.
Despite a rapid increase in the number of publications on the subjects related to pharmacogenetics / pharmacogenomics in the last decade, it’s not enough. Furthermore, topics like drug repurposing, epigenetics and data analysis could give answers to many questions in order to more elucidate the genome-drug response relationship.
The goal of this Research Topic is to provide an overview of recent discoveries in the field of using pharmacogenetics/pharmacogenomics to improve anticancer treatment. We welcome submissions of various types of manuscripts, including high-quality original research papers, reviews, and methods. We welcome topics including, but not limited to:
? The relationship pharmacogenes-drug response
? New genes involved in the effect of anticancer drugs
? New genes involved in the side effects of anticancer drugs
? How drug repurposing could help the study of interaction genome-anticancer drug response
? Could epigenetics modification be involved in the interaction pharmacogenetic-anticancer drug effect
? How data analysis could help to understand the relationship pharmacogenetic-drug response
Anticancer treatment has been impacted significantly by genomics in the last decade. In fact, the therapeutic effect and/or adverse events of a given drug is highly influenced by the genotype of the patient. Pharmacogenomics / Pharmacogenetics, which studies the interaction of genome-drug response, can evaluate the associations between drug efficacy/toxicity and variation in drug pharmacokinetics and pharmacodynamics characteristics. These characteristics include biotransformation, interactions with the receptor and other drug targets, and drug transport. All these mechanisms, controlled often by pharmacogenes, could lead to the resistance of cancer cells by exposing it to a lower therapeutic dose of the active molecule. By understanding the relationship between genome variation and drug response, we can optimize and improve anticancer treatment of the patient, called personalized or precise medicine.
Recently, new genetic variants related to anticancer therapy and cancer resistance, a major obstacle for successful anticancer treatment, have been found due to the technology of next generation sequencing. Furthermore, scientists estimate that the number of variants in pharmacogenes, for example cytochrome P450 genes, ATP-binding cassette (ABC) transporters, and others, are much greater than predicted. Also, most variant alleles in pharmacogenes are rare variants (minor allele frequency (MAF) < 1%) and it has been reported that these alleles play an important role in the pharmacogenomic / pharmacogenetics prediction of drug response.
Despite a rapid increase in the number of publications on the subjects related to pharmacogenetics / pharmacogenomics in the last decade, it’s not enough. Furthermore, topics like drug repurposing, epigenetics and data analysis could give answers to many questions in order to more elucidate the genome-drug response relationship.
The goal of this Research Topic is to provide an overview of recent discoveries in the field of using pharmacogenetics/pharmacogenomics to improve anticancer treatment. We welcome submissions of various types of manuscripts, including high-quality original research papers, reviews, and methods. We welcome topics including, but not limited to:
? The relationship pharmacogenes-drug response
? New genes involved in the effect of anticancer drugs
? New genes involved in the side effects of anticancer drugs
? How drug repurposing could help the study of interaction genome-anticancer drug response
? Could epigenetics modification be involved in the interaction pharmacogenetic-anticancer drug effect
? How data analysis could help to understand the relationship pharmacogenetic-drug response
